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Abstract: Objectives: Pyrrolizidine alkaloids (PA) exist ubiquitously in our environment. More than
6000 plants, about 3% of the world’s flowering plants, are known to synthesize PA. As a consequence,
many herbal ingredients, including St. John’s wort (SJW), are contaminated with PA that can possess
acute and subchronic toxic effects as well as mutagenic and genotoxic properties. Therefore, the
possible benefits of SJW as an herbal remedy against depression need to be weighed against the
possible risks of unwanted PA intake. Methods: We searched the literature regarding the current
knowledge on PA and evaluated the evidence on the antidepressant effects of quantified SJW extract
based on a Cochrane Review and the current practice guidelines on depression. Risks are depicted
in form of a risk ladder and benefits in form of an icon array. Results: Evidence from clinical
studies indicates that quantified SJW extract is an effective treatment option for mild to moderate
depression with fewer side effects than conventional antidepressants. Health statistics from different
countries do not quantify cases of death caused by PA intake. However, deaths due to suicide, often
triggered by depression, are common (11 in 1000 in Germany in 2015) and rank between fatalities
due to liver diseases (16 in 1000) and household accidents (10 in 1000). Conclusions: Quantified SJW
extract is a safe and effective treatment option, and its potential of treating depression outweighs the
(hypothetical) risk of unwanted PA intake.
Keywords: pyrrolizidine alkaloids (PA); risk-benefit analysis; St. John’s wort extract (SJW)
1. Introduction
Pyrrolizidine alkaloids (PA) that exist ubiquitously in our environment possess mutagenic and
genotoxic properties and can induce acute and subchronic toxic effects [1]. More than 6000 plants
(about 3% of the world’s flowering plants) are known to synthesize more than 660 different PA [1–4].
Thus, PA can contaminate many biological products, such as foodstuff, beverages (milk, teas, and
herbal infusions), and herbal remedies [4–6].
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The case of St. John’s wort (SJW, hypericum perforatum) is of particular importance because
it is a popular therapeutic option for one of the major diseases of modernity, namely depression [7].
The present paper puts PA-related risks resulting from temporary use of SJW in perspective with more
general health and everyday life risks.
2. Pharmacological Effects of St. John’s Wort (SJW) in the Treatment of Depression: Clinical
Studies, Side Effects, and Guidelines
2.1. Definitions
In Europe, the use of SJW as a medical remedy against depression has been documented since
the first century AD [8]. However, in the context of this review SJW is considered for the group of
herbal medicinal products with well-established use as defined in the Community herbal monograph
on Hypericum perforatum L., herba (well established medicinal use): Herbal preparations with a dry
extract (DER 3–7:1), extraction solvent methanol (80% v/v) or a dry extract (DER 3–6:1), extraction
solvent ethanol (80% v/v) or a dry extract (DER 2.5–8:1), extraction solvent ethanol (50–68% v/v) [9].
Therefore, we will use the terms “SJW” and “quantified SJW extract” synonymously in this review.
The diagnoses of a depressive/major depressive episode overlap considerably [10]. This terminological
indistinctiveness is also seen in clinical studies on depression. The title of the Cochrane review that
we are going to describe below (see Section 5.2) reads “St. John’s wort for major depression” [11].
Later on in the review it is specified that “the severity of depression was described as mild to moderate
in 19 trials, and as moderate to severe in 9 trials” ([11], page 7).
2.2. European and Chinese Studies
SJW is considered a medicinal product in Europe and China but a finished dietary supplement
product in the United States (U.S.). Therefore, we present the following studies according to this
geographical distinction.
In 2010, the large body of evidence resulting from the controlled use of standardized SJW in
Europe has resulted in a “Community herbal monograph on hypericum perforatum” [12]. In this
monograph, two distinct usages of SJW in solid dosage form are summarized for oral application,
one for the treatment of mild to moderate depressive episodes (according to ICD 10) and the other
for the short-term treatment of symptoms of mild depressive disorders. SJW is a prominent example
of the successful translation of experience-based medicinal knowledge into a modern concept of
evidence-based phytopharmacy.
Preclinical and clinical studies on SJW have been predominantly conducted in German-speaking
countries with herbal medicinal products containing standardized extracts [13]. In vivo and in vitro
studies have consistently shown that SJW acts on dopaminergic, serotonergic, and noradrenergic
systems with complex effects. These activities are mediated by different types of constituents
with hyperforin and probably hypericin as the main active ingredients. Animal pharmacology
showed SJW to be active in behavioral models of depression, including learned helplessness and
forced swimming tests. The experimental pharmacology of SJW has been investigated in numerous
studies [14,15]. Consequently, the main human indication for SJW has been established in patients
with mood disorders.
A Cochrane Review [11] has suggested that SJW is better than placebo and as effective as
conventional standard antidepressants for mild to moderate depression but with fewer side effects.
In the same vein, a more recent review [16] including 6993 patients from 35 studies has shown that
SJW given as a monotherapy for mild to moderate depression is superior to placebo in improving
symptoms and not significantly different from the conventional verum control drugs. Adverse events
of SJW were comparable to those of placebo and fewer than those reported for standard antidepressant
medication. A meta-analysis comparing SJW with selective serotonin reuptake inhibitors (SSRIs) in
adults comprised 27 studies with 3126 patients, including 1177 patients from the People’s Republic
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of China [17]. The authors concluded that the efficacy of SJW is comparable to that of SSRIs in the
treatment of depression, especially in the case of mild to moderate depression, but with significantly
lower rates of adverse events and withdrawals.
2.3. U.S.-American Studies
In the U.S., SJW has not been approved as a drug by the Food and Drug Administration (FDA)
but is commonly used as a finished dietary supplement product [18]. Little information is available on
the pharmaceutical quality of these dietary supplements.
Recommendations by the National Center for Complementary and Integrative Health (NCCIH)
focus on two clinical studies sponsored by the U.S. government [18]. Both studies were three-arm
studies, one using sertraline and the other citalopram as active comparators. In both studies, the
standard verum treatment and the SJW preparation failed to demonstrate significant superiority
over placebo. This result may be due to the low sensitivity of the main outcome measures Hamilton
Depression Scale (HAM-D total) and Clinical Global Impression Score (CGI) as well as due to a
high placebo response [19,20]. In consequence, NCCIH statements do not support the use of SJW
containing supplements for persons with depressed mood and underline possible risks associated
with self-medication with SJW supplements.
2.4. Side Effects of SJW
Side effects of SJW become particularly apparent in combination with other substances, such
as cyclosporine, tacrolimus, amprenavir, indinavir, and other protease inhibitors, irinotecan and
warfarin. To avoid interactions with substances metabolized by CYPP3A4, CYP2C9, CYP 2C19,
or P-glycoprotein, special care is recommended in the case of concomitant use, as specified in the
European Community Monograph and matched by national professional product information [12,21–25].
Because oral contraceptives are among those drugs, women taking the pill are advised to use additional
contraceptive measures. In the absence of sufficient data, use in patients under 18 years and during
pregnancy and lactation is not recommended [12]. Furthermore, intense UV-exposure should be
avoided. Hypericin and related naphthodianthrones cause phototoxicity due to UV light sensitivity,
which has been shown in experiments (in vitro and in vivo) and in humans [26].
Therapy with SJW should follow a medical rational [4], should be administered as a monotherapy,
and is not suitable for polypharmacy. SJW products are not sufficiently investigated to be recommended
for combination therapy with psychotropic drugs or medications for other indications. The interaction
potential limits SJW use in combination protocols [24,27].
2.5. Guidelines and Cross-Cultural Differences
The indications given in EMA/HMPC Monographs reflect the consensus of the representatives
of the national regulatory bodies represented in this committee. The mission of this committee is to
support the harmonization of the European Market by providing unified opinions. On the other hand,
in 2009 the German Federal Institute for Drugs and Medicinal Products (BfArM) approved SJW herbal
medicinal products with the indication moderate depression mandating a prescription-only status.
Therefore, it may be superior to rely on the published original clinical data and meta-analyses when
assessing the efficacy and safety of herbal medicinal products and not limit the focus towards the
(non-binding) HMPC statements.
The current German national healthcare guidelines for unipolar depression are based on a
consensus of representatives from all major medical societies and professional associations in Germany,
self-help groups, and associations of family members and relatives [28]. Antidepressants should
generally not be used for the initial treatment of mild episodes but may be indicated based on a
patient’s wishes and preferences, a patient’s positive experiences in the past, continued symptoms after
alternative interventions, and if recurrent episodes of depression are known from a patient’s history.
Drug treatment is recommended for acute moderate depressive episodes. SJW is frequently prescribed
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due to the perceived better side effect profile. However, since the constituents of the SJW extract differ
among individual manufacturers, the effectiveness cannot be extrapolated from one extract to another.
Thus, only medicinal products with clinically documented efficacy should be used [29]. Furthermore,
the specific side effects of SJW and interactions with concomitant medication have to be considered
(see Section 2.4).
The guideline on the treatment of adult patients with major depressive disorders issued by the
American College of Physicians refers to the same studies on SJW as the German guideline. However,
the guideline does not give a recommendation in favor of SJW because “St. John’s wort is not currently
regulated by the U.S. Food and Drug Administration, and there is no current standard in place about
the contents and potency of the medication. Therefore, patients in the United States may not be able to
get a quality-controlled medication or reliably obtain preparations with similar effectiveness as those
used in the included studies” [30].
It becomes evident that there is a cross-cultural element to the use and recommendation of SJW.
In Europe, SJW has been in use for decades, and pharmacological standards for the production of
SJW-based medicinal products have been established. This is not the case in the U.S., with no FDA
regulation on the making and use of SJW products being in effect.
3. SJW Contamination with PA
Generally, there are four ways of how PA can enter the human food chain (Figure 1):
1. Contamination with PA-synthesizing weed in agricultural cultivations [1,2]: PA contamination of
tea and herbal infusions is frequent and attributed to contamination of the raw materials that are
harvested along with PA-forming weeds [4].
2. Contamination of pollen of plants and resulting bee products such as honey: The PA content of
honey has been shown to be directly proportional to the amount of PA pollen in honey, and the
transfer of PA from pollen to honey occurs rather quickly [31].
3. Direct, accidental, or excessive consumption of PA-synthesizing plants: In Germany, borage
(Borago officinalis) is a prominent example. This herb is one of the characteristic ingredients of
“Frankfurt Green Sauce”, a traditional dish in the State of Hesse [32,33].
4. PA-contamination of feed given to livestock: Such contamination may result in low level PA
contamination in the foods produced by the animals such as milk and eggs.
From the available analytical data, it can be summarized that the PA burden for the general
population results primarily from the consumption of tea and herbal infusions [2,34].
Nevertheless, SJW may be contaminated with PA. In Europe, the European Medicines Agency
(EMA) and the national regulatory bodies cooperate with herbal pharmaceutical companies and
associations to keep PA contamination in herbal medicinal products as low as possible. At present,
patient exposure to PA from herbal medicinal products should not exceed a daily intake of 1 µg.
For the future, EMA strives for a limit value of 0.35 µg per day [35]. In 2016, SJW tablets were recalled
from the UK market [36] because of higher than recommended levels of PA. A recent survey from
German supermarkets, drugstores, and pharmacies identified that SJW products frequently contain
PA concentrations above the recommended values of the European and German regulatory bodies.
Only about 30% of the drawn samples were of accurate quality [37].
This low percentage highlights the importance of regulatory controls. In Europe, the legal
constraints for manufacturers of herbal drugs are generally stricter than for foodstuff due to different
legal systems: in principle, food is assumed to be safe, whereas drugs must show a positive risk-benefit
ratio before market approval, and post-marketing surveillance is mandatory. The rigid regulatory
standards of medicinal products compared to food regulations help to monitor the burden from PA
contamination in this product category [35,38]. In 2016, a detailed “Code of practice to prevent and
reduce PA contaminations of medicinal products of plant origins” has been published by German
manufacturer associations [39].
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SJW herbal medicinal products are used for the symptomatic treatment of mood disorders and
depression; hence, doses and length of treatment vary. The length of controlled clinical trials ranges
between 4 to 12 weeks [17]. In general, treatment periods with SJW are in the order of magnitude
of months but not years. When using SJW, the exposure time of possible PA contamination of this
herbal product is clearly less than that of people who regularly drink tea or herbal infusions that are
frequently contaminated with PA. As a single source, PA contamination of herbal medicinal products
with SJW as the active ingredient is irrelevant. The many possible origins of PA contamination [40]
underline the necessity to substitute the pure risk analysis with a specific risk-benefit analysis.
4. PA Toxicity: Detectability, Metabolism, and Serious Health Consequences
The progress in recent years in PA analytics (HPLC and tandem mass-spectrometry) has resulted
in the ability to detect PA at trace levels in nearly every part of the human environment [41,42].
Harmonization of methods to achieve comparable results in different chemical laboratories still needs
to advance further [2,3,43–46]. Better detection methods should not be confused with an overall
increase in PA occurrence [35], for which there is no evidence [2,3,6,47].
Toxicity requires metabolic activation involving cytochromes P-450 and flavin-containing
monooxygenases [5]. Toxification and detoxification pathways are interrelated and vary greatly
within and among species, the two sexes, individuals, and over time [48–50].
We have recently reviewed the PA experimental toxicology and related findings in humans [4].
Hepatotoxicity is the main effect after PA exposure. Pulmonary toxicity is sometimes seen after
exposure to hepatotoxic PA. The same structural requirements and the same metabolites are necessary
for liver and lung toxicity. The more stable the dehydropyrrolizidine metabolites, the easier can they
be transported away from the liver and cause toxic effects in other organs.
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Consumption of high doses of PA may result in veno-occlusive liver disease, the occlusion of
central venules [51–53]. Case reports associated with PA-contaminated grain have been reported in
Pakistan, India, and Afghanistan. This type of massive grain contamination with PA-synthesizing
plants is unlikely to occur in modern professional agricultural systems [54].
PA-contaminated food has never been studied for carcinogenicity in long-term animal studies.
Any carcinogenic effect due to PA exposure would be expected to follow long-term, low-dose exposure.
Many human environmental carcinogens manifest only after long latency periods, thus early in life
exposure, and life-time burden seems more important in adulthood than short-term exposure [55].
However, hepatic vein occlusion, mutagenicity, genotoxicity, and carcinogenicity of PA and
PA-containing plant extracts have been studied since the mid-1970s [56] and evaluated by the
International Agency for Research on Cancer (IARC) resulting in categorization as Group 2B (possibly
carcinogenic to humans) or Group 3 (not classifiable as to its carcinogenicity to humans). Lasiocarpine,
monocrotaline, and riddelliine are Group 2B carcinogens [57–59]. Mechanistic studies have shown
dehydropyrrolizidine to form DNA adducts that could well be the causal mode of action resulting in
mutagenicity and cancerogenicity [3,60].
In rodents, the signal tumor of long-term PA poisoning is hepatic hemangiosarcoma [61,62].
Additionally, hepatocellular adenoma and carcinoma have been reported [63]. If rare tumor types
found in humans correspond to tumors seen in animals exposed to the same suspected carcinogenic
agent, such findings are accepted as a strong empirical argument for causality. About 50% of the
products identified by IARC as carcinogenic to humans show comparable organotropism and tumor
pathology in animals. Human carcinogens associated with liver carcinoma and hemangiosarcoma
include Alpha-emitters, vinyl chloride, and arsenic. Corresponding tumors can be induced in
animals [4,64,65].
Detoxification capacity by glutathione conjugation in sinusoidal cells is less than in hepatocytes
due to lower glutathione content, leading to higher intercellular exposure to toxic free radicals.
An overload of the intracellular detoxification systems prompts the hepatotoxicity of monocrotaline.
This observation suggests a threshold dose for this type of toxicity.
The incidence of human hepatic hemangiosarcoma is very low [66,67]. No evidence exists
for an increase in this tumor type over time, and no epidemiological data show any association
between chronic low-dose PA exposure and human disorders [2,35,43]. Angiosarcoma derives from
endothelial cells of blood vessels or lymphatic vessels. Angiosarcoma is estimated to account for
2-3% of all types of soft tissue sarcoma, and primary hepatic angiosarcoma accounts for <5% of all
types of angiosarcoma. Based on epidemiological data from Norway, Sweden, the UK, and the U.S.,
a review yielded an annual incidence of 0.5 to 2.5 cases per 10,000,000 individuals. Among those cases,
20–25% can be linked to known etiologic factors, for instance vinyl chloride monomers [68–71] that
are used to produce polyvinyl chloride, a widely used plastic. The IARC has classified polyvinyl
chloride as a carcinogen with sufficient evidence of inducing hemangiosarcoma of the liver in exposed
workers. There is also strong evidence that polyvinyl chloride induces hepatocellular carcinoma
as an occupational disease [64]. No evidence has been produced to link environmental exposure
to vinyl chloride monomer with human angiosarcoma of the liver [67]. The goal of effective risk
assessment is to prevent morbidity and mortality in humans. Therefore, risk assessment is based on
instances that are observable and quantifiable. Certainly, we cannot exclude unknown facts, which
leaves room to speculate about the theoretical risk of human tumors of unknown organotropism
and their association with low-dose PA exposure in the case of unknown, but specific individual
disposition. However, risk assessment is considered an evidence-based discipline that should provide
state-of-the-art information about specific quantified health issues [4,40,43,72–75].
Taking the extensive follow-up reports on human PA exposure into account, Prakash et al.
concluded that the human risk of veno-occlusive disease and childhood cirrhosis are established but
also that PA are not carcinogenic to humans [76].
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From a scientific standpoint, however, we must adhere to the principle “absence of evidence is not
evidence of absence” [4,77]. Thus, just because we could not find any PA-induced tumors in humans,
the counter argument that a PA-tumor link does not exist is not confirmed. Nevertheless, what we
can infer from the current evidence is that the risk of human angiosarcoma due to PA contamination
must be so small that it cannot be quantified through health statistics (see Table 1). In contrast, other
well-known health or everyday life risks (e.g., suicide and household accidents) are preventable but
still exist and are rarely addressed in public debates.
Table 1. Risk ladder.
Death Cases 2015 *Germany
2008 *
Germany
2016 **
World
2014 ***
Switzerland
2014 ****
United States
Absolute number of deaths 925,200 844,439 54,700,000 63,938 2,626,418
Standardized at 1000 cases
Cardiovascular disease 385 420 323 328 234
Cancer 250 257 163 262.3 225
Diabetes mellitus 26 26 58.3 19 29
Liver diseases 16 18 23 14.4 ***** 15
Suicide 10.9 11.1 14.9 16 1 16
Household accidents 10 8.1 23 2 10.3 6.9
Liver cancer 8.5 8.3 12.3 ***** 9.4 9.4
Traffic accidents 3.8 5.5 24.5 3.6 12.8
Liver cancer (unexplained cause) 1.7 0.9 ***** 3.5 ***** 1.8 ***** 2.1 *****
PA-related death 1 ? ? ? ? ?
1: Suicide and assisted suicide; 2: (2015); * Source: Federal Statistical Office, Germany, Annual Report 2015
and 2008; ** Source: www.ourworldindata.org (Global Burden of Disease (GBD); *** Sources: bfu—Swiss
Council for Accident Prevention. STATUS 2017; https://www.bfs.admin.ch/bfs/de/home/statistiken/
gesundheit/gesundheitszustand/sterblichkeit-todesursachen/spezifische.html#par_text; https://www.nzz.ch/
schweiz/aktuelle-themen/krebskranke-mehr-patienten-und-tieferes-sterberisiko-ld.9031. *** Source: https:
//www.nzz.ch/schweiz/aktuelle-themen/krebskranke-mehr-patienten-und-tieferes-sterberisiko-ld.9031. ****
Sources: https://www.cdc.gov; https://www.asecurelife.com. ***** Source: https://vizhub.healthdata.org/cod/. ?
unknown, not listed in any death statistics.
Regarding primary liver cancer, we calculated the total number of liver cancer minus the number
of cancers attributable to risks from known sources for the U.S. [4]. The conservative estimate of annual
new cases not due to hepatitis is below 5000. These <5000 cases must include all cases from known
risk factors, excluding hepatitis B and C. Major well-established risk factors are obesity, metabolic
syndrome and diabetes, hemochromatosis, alcohol consumption, and aflatoxin in warmer and tropical
countries [78].
Taking the conceptions on the mode of action for chronic PA toxicity together with the
experimental findings in long-term animal studies, we should expect hemangiosarcoma of the liver
and hepatocellular carcinoma to be the most likely results after long-term and low-dose PA exposure
in humans [4]. Nevertheless, given the low prevalence of hemangiosarcoma, the causal contribution
of PA contamination must be very small compared to the impact of the sum of primary liver cancer
attributable to all well-recognized sources.
5. Balanced Risk-Benefit and Risk Communication
In the light of the potentially harmful effects of PA and the clinical data available on SJW that so
far failed to provide evidence for a human link between PA and SJW, we try to put benefits and possible
risks into a broader perspective. More specifically, we will quantify and summarize the benefits and
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potential risks of SJW intake as an herbal medication for mild and moderate depression, using two
established risk communication tools, namely risk ladder and icon array.
5.1. Rationale for and Methods of Compiling the Risk Ladder
The risk ladder is a standard method to show risks in perspective by ranking common causes
of death in a descending order. Our source data are original counts and numbers as reported in
statistical reports and data bases that are standardized by applying a common anchor. Thereby,
the relative size of diverse everyday risks and health risks becomes apparent. Such risks ladders
provide astonishing insights, for instance that suicides are more frequent than traffic accidents.
One major reason for such surprise experiences is the availability heuristic, which renders cognitive
contents that are highly publicized and thus readily available to be associated with higher levels of
risks [79]. This preconception often breaks down when one looks at the real evidence.
For the risk ladder, we selected major illnesses responsible for major health costs, such as
cardiovascular disease, cancer, diabetes, diseases that may be caused or aggravated by toxic substances
(including PA), such as liver disease or liver cancer, and common everyday fatalities, such as traffic
or household accidents. In order to allow for a representative comparison of relative risks over time
and across countries, we consulted different sources: official death statistics issued by the German
Statistical Federal Agency, the Swiss Statistical Federal Agency, the Center for Disease Control (CDC),
and the Global Burden of Disease (GBD) Collaboration (all respective web links can be found below
Table 1).
The German cause of death statistics is an annual census [80]. The data are based on the official
death certificates that are transferred from the health authorities to the statistical offices of the federal
states. In the case of missing or implausible information, the health authorities clarify the discrepancies
with the doctors. Cause of death is coded according to the ICD 10, ensuring the international
comparability of the data. Inaccuracies may arise from the information provided by physicians
and the subjective evaluation of the causes of death in the statistical offices of the federal states.
In order to minimize such errors, data are continuously random-checked. The findings are used for
the annual training of specialist staff in the statistical regional offices.
Likewise, the Swiss cause of death statistics are based on a census [81]. The percentage of missing
information on the cause of death is estimated to be 2%. The standardization of data collection and the
use of the ICD code guarantee good international comparability.
CDC.gov is the official Web site of the CDC, which is the leading U.S. public health institute under
the Department of Health and Human Services (headquartered in Atlanta, Georgia). CDC.gov is a
public domain website providing direct access to important health and safety topics, scientific articles,
data, statistics, tools, and resources.
Our World in Data is an online publication providing an array of statistics on changing living
conditions that is produced and maintained by the University of Oxford as a public good. Data stem
from different sources, namely specialized institutes, research articles, international institutions, and
international statistics. A key is the GBD collaboration that employs a standardized approach to the
attribution of deaths to specific causes based on limited data [82]. The GBD mortality cause assessment
is in accordance with and strongly tied to categories as defined within the ICD.
5.2. Methods of Compiling the Icon Array
Icon arrays consist of a matrix of icons that represent a population at risk and simultaneously
display the number of events (e.g., responders) and non-events (e.g., non-responders) [72,83].
Icon arrays have the property to visualize at one glance the part-whole relationship and can also
be used to depict features other than efficacy (e.g., responders vs. non-responders), for instance side
effects (e.g., suffering from a special side effect vs. not suffering from a special side effect). Furthermore,
to compare benefits and risks of different kinds of treatments (e.g., standard antidepressant vs. SJW vs.
placebo), three icon arrays—one for each treatment—can be depicted side by side. In the present icon
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array (Figure 2), the summary of chances and risks are also depicted numerically on the bottom of the
icon array, following the idea of icon boxes of the Harding Center for Risk Communication [84].
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Figure 2. Icon array-graphic depiction of the Linde et al. (2008) Cochrane Review [11].
The present icon array is based on the Cochrane Review by Linde et al. [11], which is the most
comprehensive and most prestigious review on SJW. The Cochrane Review was based on 29 RCTs.
A variety of hypericum preparations were investigated, and in most trials the extract doses ranged
between 500 to 1200 mg. Standard antidepressants were used as active comparators. The Cochrane
Review presents absolute numbers (not only relative risk reductions), which are necessary to generate
icon arrays. In contrast, more recent reviews published in 2016 presented relative risks and were
therefore not included in the icon array. It is important to note, however, that the 2016 reviews echo
the conclusion drawn from the Cochrane publication [16,17]. The review conducted by the Chinese
author group was based on 27 RCT that compared standardized SJW extracts to SSRIs. The RCTs
were conducted in Brazil, Canada, Denmark, Germany, the People’s Republic of China, and the USA.
The quantified SJW extracts included Calmigen, Iperisan, LI-160, LoHyp-57, STW3, WS5570, and Ze117
and were typically administered in a dosage of 900mg/d for 6 to 12 weeks [17]. The same is true for
the analysis by Apaydin et al. [16].
Thus, the available body of knowledge on clinical data with regard to SJW has not changed over
the past decade.
5.3. Interpretation
Risk comparison within a risk ladder improves risk understanding [72–74,85]. The risk ladder
shown in Table 1 compares the death rates of major health risks as well of everyday life risks
that should help to put the possible risk of PA contamination from SJW medicinal products into
perspective. Comparing figures from different sources and for different cohorts show a consistent
order of magnitude. Deaths from cardiovascular diseases and cancer by far dominate all other life risks.
Fatal household accidents and traffic accidents in developed countries are outnumbered by the risk
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from suicide. Neuropsychiatric diseases are the number one risk factor of suicidal death. Depression
accounts for up to 60% of suicides [86–88]. Evidence indicates benefits of antidepressant medication
in patients who experience suicidal thoughts and are prone to suicidal behavior [89]. A recent
meta-analysis of the efficacy and acceptability of 21 antidepressants published in the Lancet [90]
showed all individual medications to be superior to placebo when comparing an 8-week period
after the onset of treatment. The Lancet review did not mention SJW, probably because SJW is a
non-prescription herbal remedy in the UK. The cross-cultural component in assessing SJW has already
been noted earlier. However, in controlled clinical trials, quantified SJW extracts have shown to be
superior to placebo and as effective as synthetic antidepressants, both classic tryciclics and newer
SSRIs [12,27]. Nevertheless, the safety profile of SJW as indicated by dropout rates from clinical studies
and unwanted drug effects is in the placebo range. Thus, lower withdrawal from studies due to
adverse events by SJW is an advantage in the management of major depressive disorders [91].
Based on the current combined evidence on efficacy, side-effect profile, and adherence, the use
of quantified SJW extract as monotherapy in patients with mild to moderate depression is a
rational choice.
6. Points to Consider and Conclusions
PA contamination in the human environment has been recognized for decades. Recently, interest
has risen due to improved analytical methods and a steadily increasing number of analytical reference
standards for individual PA. No evidence exists for an increase in PA uptake in the general population
in the past. Main sources for PA contaminants in humans are food, beverages, supplements, and herbal
remedies. For the general population, beverages and foodstuff derived from natural sources are more
important than supplements and herbal drugs. A major impact results from habitual drinking of tea
and herbal infusions. In a recent project, we have performed a risk-benefit analysis to balance possible
human risks associated with PA contamination with the benefits resulting from drinking tea and herbal
infusions. We concluded that the benefits of drinking tea and herbal infusions clearly outweigh the
health risk of possible PA contamination that was judged to be negligible [4].
In the present paper, we extend our risk-benefit analysis to herbal medicinal products, choosing
SJW as a prominent and widely used agent. Patients taking contaminated herbal medicinal products
(or supplements resulting from natural sources) add a treatment-specific possible PA burden to
their background exposure for a limited time. For herbal medical products used according to the
Community Monograph on SJW [12], clinical effectiveness comparable to that of conventional SSRI
has been established; adverse events were comparable to placebo, and side effects were fewer than
seen with standard antidepressant medication. This clearly makes SJW herbal medicinal products
suitable as a first line medical treatment option for patients with mild to moderate depression,
particularly for patients who favor phytotherapy over conventional medicinal products. Upper limits
for PA contamination for herbal drugs exist and the number of depressive patients on long-term SJW
treatment is limited. Thus, the additional PA exposure during drug treatment is expected to stay well
within the boundaries given for the general population by differences in interindividual life style and
nutrition [2,5,34,35].
This conciliatory conclusion, however, is no excuse for manufacturers to discontinue their efforts
to continuously secure good product quality and be transparent in their measures to achieve this goal,
since a recent analysis has clearly shown room for improvement [79].
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